MedChemComm · 2014 · 200 citations · 92 references
PharmacyMolecular BiologyPharmacologyMolecular PharmacologyNucleic Acid BiochemistryNucleic Acid ChemistryModified Nucleic AcidsNucleic Acid EngineeringNucleic Acid ModificationNucleic Acid SynthesisNucleobase ChemistryOligonucleotide ChemistryAntisense RnasChemical Modification Of OligonucleotidesNucleoside AnalogsNucleotide AnalogsOligonucleotide Backbone ModificationsOligonucleotide DeprotectionOligonucleotide SynthesisOligonucleotide Therapeutics
There has been an upsurge in the number of clinical trials involving chemically modified oligonucleotide-based drug candidates after the FDA approval of Vitravene, Macugen, and recently, Kynamro. Over the years, different types of backbone, nucleobase and/or sugar-modified oligonucleotides have been synthesized because natural DNA/RNA based oligonucleotides pose some limitations, such as poor binding affinity, low degree of nuclease resistance, affecting their direct use in antisense therapeutics. In this review article, we discuss in detail different modifications of nucleosides/oligonucleotides along with the related clinical trials, which demonstrated their potential as drug candidates for antisense and related nucleic acid based therapeutics.
92
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat
Claudia Carrieri, Laura Cimatti, Marta Biagioli et al. · Nature · 2012 · 1K citations · Full text